Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC
Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.
EP: 1.Overview of First-Line Combination Therapy in Advanced Clear Cell RCC
EP: 2.Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC
EP: 3.Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
EP: 4.Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC
EP: 5.Selecting Therapy for a Real-World Patient With Clear Cell RCC
EP: 6.Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
EP: 7.Second-Line Treatment Armamentarium in Clear Cell RCC
EP: 8.Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
EP: 9.Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
EP: 10.Renal Cell Carcinoma: Future Evolutions in Care
EP: 11.Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)
EP: 12.Available Treatment Options for Patients with Advanced RCC
Now Viewing
EP: 13.Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC
EP: 14.Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC
EP: 15.Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC
EP: 16.Key Takeaways in the Treatment of Advanced RCC From KCRS 2023
EP: 17.Future Perspectives in the Treatment of Advanced RCC
Related Videos
